| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.82▲ | 3.82▲ | 3.73▲ | 3.85▲ | 3.90▲ |
| MA10 | 3.65▲ | 3.65▲ | 3.62▲ | 3.76▲ | 3.58▲ |
| MA20 | 3.65▲ | 3.67▲ | 3.66▲ | 3.83▲ | 4.23▼ |
| MA50 | 3.79▲ | 3.85▲ | 3.80▲ | 3.51▲ | 3.78▲ |
| MA100 | 3.67▲ | 3.57▲ | 3.52▲ | 4.38▼ | 24.74▼ |
| MA200 | 3.48▲ | 3.49▲ | 3.72▲ | 4.14▼ | 184.59▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.052▲ | 0.050▲ | 0.031▲ | 0.014▲ | 0.101▲ |
| RSI | 60.909▲ | 60.104▲ | 59.987▲ | 57.225▲ | 46.548▼ |
| STOCH | 79.104 | 79.104 | 70.175 | 71.455 | 45.264 |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -10.360▲ | -56.343 |
| CCI | 166.836▲ | 166.441▲ | 217.011▲ | 161.280▲ | 1.291 |
|
Tuesday, April 07, 2026 05:28 AM
Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The trial has ...
|
|
Monday, March 30, 2026 05:16 AM
Immunology™, Evaxion has,in collaboration with the Gates Foundation, developed novel design concepts for polio vaccines potentially superior ...
|
|
Thursday, March 19, 2026 06:00 AM
COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 08/04/26 | 4.00 | 4.01 | 4.00 | 4.01 | 10,131 |
| 07/04/26 | 3.57 | 3.80 | 3.3273 | 3.80 | 13,590 |
| 06/04/26 | 3.86 | 3.86 | 3.57 | 3.725 | 15,847 |
| 02/04/26 | 3.71 | 3.8704 | 3.61 | 3.78 | 3,481 |
| 01/04/26 | 3.71 | 3.94 | 3.608 | 3.94 | 20,767 |
| 31/03/26 | 3.61 | 3.7231 | 3.51 | 3.72 | 20,588 |
| 30/03/26 | 3.66 | 3.86 | 3.36 | 3.77 | 37,536 |
| 27/03/26 | 3.58 | 3.58 | 3.31 | 3.52 | 30,243 |
| 26/03/26 | 3.76 | 3.76 | 3.58 | 3.59 | 18,196 |
| 25/03/26 | 3.65 | 4.00 | 3.58 | 3.70 | 10,034 |
|
|
||||
|
|
||||
|
|